



**University of Dundee**

**Improving the predictive power of xenograft and syngeneic anti-tumour studies using mice humanised for pathways of drug metabolism**

Henderson, Colin J.; McLaren, Aileen W.; Kapelyukh, Yury; Wolf, C. Roland

*Published in:*  
F1000 Research

*DOI:*  
[10.12688/f1000research.122987.2](https://doi.org/10.12688/f1000research.122987.2)

*Publication date:*  
2023

*Licence:*  
CC BY

*Document Version*  
Publisher's PDF, also known as Version of record

[Link to publication in Discovery Research Portal](#)

*Citation for published version (APA):*

Henderson, C. J., McLaren, A. W., Kapelyukh, Y., & Wolf, C. R. (2023). Improving the predictive power of xenograft and syngeneic anti-tumour studies using mice humanised for pathways of drug metabolism. *F1000 Research*, 11, Article 1081. <https://doi.org/10.12688/f1000research.122987.2>

**General rights**

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



## BRIEF REPORT

# REVISED Improving the predictive power of xenograft and syngeneic anti-tumour studies using mice humanised for pathways of drug metabolism [version 2; peer review: 2 approved]

Colin J. Henderson , Aileen W. McLaren, Yury Kapelyukh, C. Roland Wolf

Division of Systems Medicine, School of Medicine, University of Dundee, Ninewells Hospital, Dundee, Tayside, DD1 9SY, UK

**V2** First published: 21 Sep 2022, 11:1081  
<https://doi.org/10.12688/f1000research.122987.1>

Latest published: 27 Mar 2023, 11:1081  
<https://doi.org/10.12688/f1000research.122987.2>

## Abstract











Drug development is an expensive and time-consuming process, with only a small fraction of drugs gaining regulatory approval from the often many thousands of candidates identified during target validation. Once a lead compound has been identified and optimised, they are subject to intensive pre-clinical research to determine their pharmacodynamic, pharmacokinetic and toxicological properties, procedures which inevitably involve significant numbers of animals - mainly mice and rats, but also dogs and monkeys in much smaller numbers and for specific types of drug candidates. Many compounds that emerge from this process, having been shown to be safe and efficacious in pre-clinical studies, subsequently fail to replicate this outcome in clinical trials, therefore wasting time, money and, most importantly, animals.


Due to high rates of metabolism and a differing spectrum of metabolites (some pharmacologically active) in rodents, species differences in drug metabolism can be a major impediment to drug discovery programmes and confound the extrapolation of animal data to humans. To circumvent this, we have developed a complex transgenic mouse model - 8HUM - which faithfully replicates human Phase I drug metabolism (and its regulation), and which will generate more human-relevant data from fewer animals in a pre-clinical setting and reduce attrition in the clinic.

One key area for the pre-clinical application of animals in an oncology setting - almost exclusively mice - is their use in anti-tumour studies. We now further demonstrate the utility of the 8HUM mouse using a murine melanoma cell line as a syngeneic tumour and also present an immunodeficient version 8HUM\_Rag2<sup>-/-</sup> - for use in xenograft studies. These models will be of significant benefit not only to Pharma for pre-clinical drug development work, but also throughout the drug efficacy, toxicology, pharmacology, and drug metabolism

## Open Peer Review

Approval Status 

	1	2
<b>version 2</b>		
(revision)		
27 Mar 2023	 view	 view
		
<b>version 1</b>		
21 Sep 2022		
	 view	 view

1. **Russ Prough** , University of Louisville, Louisville, USA
2. **Chris Goldring**, University of Liverpool, Liverpool, UK

Any reports and responses or comments on the article can be found at the end of the article.


communities, where fewer animals will be needed to generate more human-relevant data.

### Keywords

humanised P450 model, transgenic mice, drug metabolism, drug development, xenograft, chemotherapy, combination chemotherapy



This article is included in the **NC3Rs** gateway.



This article is included in the **Oncology** gateway.

**Corresponding author:** C. Roland Wolf ([c.r.wolf@dundee.ac.uk](mailto:c.r.wolf@dundee.ac.uk))

**Author roles:** **Henderson CJ:** Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing;

**McLaren AW:** Data Curation, Investigation, Methodology, Project Administration, Resources, Supervision, Writing – Review & Editing;

**Kapelyukh Y:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Resources, Writing – Review & Editing;

**Wolf CR:** Conceptualization, Funding Acquisition, Methodology, Supervision, Writing – Review & Editing

**Competing interests:** No competing interests were disclosed.

**Grant information:** This work was supported by a Cancer Research UK Programme Grant [C4639/A10822] and Medical Research Council Project Grant [MR/R017506/1]. Work in the CRW Lab has also been funded by NC3Rs G0700611/1 and G0500183/1.

*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

**Copyright:** © 2023 Henderson CJ *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Henderson CJ, McLaren AW, Kapelyukh Y and Wolf CR. **Improving the predictive power of xenograft and syngeneic anti-tumour studies using mice humanised for pathways of drug metabolism [version 2; peer review: 2 approved]** F1000Research 2023, 11:1081 <https://doi.org/10.12688/f1000research.122987.2>

**First published:** 21 Sep 2022, 11:1081 <https://doi.org/10.12688/f1000research.122987.1>

**REVISED Amendments from Version 1**

A sentence referring to unpublished data from our lab regarding self-induction of dabrafenib metabolism in the 8HUM mouse has been added to the text of the Results section.

In the light of the Reviewer's comment, we have changed the sentence in the Abstract regarding species differences in drug metabolism and the effects this can have on drug discovery and extrapolation of data from animals to humans.

The Reviewer is correct to point out that both rats and mice are used by industry in the drug development process. However, the utility of mice for growing xenografts, including patient-derived xenografts, and the development of 'mouse clinical trials', along with the more advanced use of mice in genetically engineered models (such as 8HUM) means that increasingly mice are being considered more useful for drug development, especially in oncology.

A sentence to this effect has been placed in the Discussion, and additional references added at the end of the bibliography.

**Any further responses from the reviewers can be found at the end of the article**

**Abbreviations**

PDX: patient-derived xenograft

p.o.: per os, oral gavage

s.c.: sub-cutaneous

**Introduction**

The pre-clinical stage of drug development provides crucial information for the decision process as to whether a drug candidate will proceed to 'first in human' and phased clinical trials.<sup>1</sup> The failure rate through the pre-clinical stages of drug development can be high and many candidate molecules taken forward to clinical trials subsequently fail to recapitulate the safety profile and efficacy found in animal studies.<sup>2-5</sup> There are many reasons for this, but significant species differences in drug metabolism between animals (rats, mice) and humans – with concomitant changes in pharmacokinetics, metabolite profiles, toxicokinetics and pharmacodynamics – are key components underlying the observed failure rates.<sup>5</sup> We have developed a sophisticated transgenic mouse model in which the major human drug metabolising enzymes – and the transcription factors regulating their expression – replace their mouse counterparts. In a previous report on this humanised mouse model<sup>6</sup> we show, using model compounds and anti-cancer drugs, that drug metabolism and disposition in the 8HUM mouse more closely reflects that found in humans. Given the growing importance of drug combinations in cancer therapy,<sup>7</sup> it is clear that a genetically engineered mouse model such as 8HUM could play a pivotal role in the development of such combinations.<sup>8</sup>

While some pre-clinical work is carried out *in vitro*, using a variety of cell lines including immortalised human cells, much – and arguably the most important – is carried out in animals, mainly rodents but also dogs, and for certain types of candidate molecules, primates. One such *in vivo* use in the pre-clinical setting is syngeneic or xenograft work, where anti-tumour efficacy of drug candidates is tested alone or in drug combinations. In a syngeneic model, murine cell lines are implanted subcutaneously or orthotopically and tumour response to candidate drugs tested. Whilst such experiments can account for the effect of immune system, the genetic background of the tumour cells – which must match that of the host animal used – can also give rise to disparate results. More recently xenograft models have come to the fore, where immunodeficient mouse lines are able to grow human tumours either from existing immortalised cell lines or via fresh tissue as patient-derived xenografts (PDX).<sup>9,10</sup> Despite lack of a competent immune system and any issues that this may potentially cause in the interpretation of results, the latter are growing in use, a good example being the EurOPDX consortium, who have a database of PDX models to share with the research community.<sup>11</sup> Notwithstanding extensive xenograft use in various guises, such models still have issues arising from retention of murine drug metabolism and disposition.<sup>8</sup>

In this brief report we showcase a modification of the humanised 8HUM model in which we have generated a compromised immune system by deleting the *Rag2* locus. Using murine and human melanoma cell lines in 8HUM\_ *Rag2*<sup>-/-</sup> mice, we show tumour growth in a syngeneic and xenograft setting, respectively, and demonstrate *in vivo* sensitivity to dabrafenib and trametinib, drugs currently used in combination as standard of care in the treatment of metastatic melanoma. Together, these models have the potential to significantly reduce the number of animals used in the pre-clinical stages of drug development, while generating more human-relevant data and thus improving the chances of a candidate drug replicating a positive pre-clinical finding in successful clinical trials.

## Methods

### Reagents

Unless specifically stated, reagents used in these studies were purchased from Sigma-Aldrich (Dorset, UK).

### Animals

Transgenic mice – 8HUM - extensively humanized for the major cytochrome P450 enzymes in Phase I drug metabolism, along with the transcription factors regulating their expression, have previously been described<sup>6</sup> and were generated in a collaboration between CXR Biosciences and Taconic Biosciences funded through the Scottish Government ITI, with CRW as one of the principal investigators.

Thirty-five murine genes (the Cyp2c (except Cyp2c44), Cyp2d and Cyp3a murine gene clusters and transcription factors Car and Pxr) were replaced by eight human genes (CYP1A1, CYP1A2, CYP2C9, CYP2D6, CYP3A4, CYP3A7, CAR, PXR). Expression of human P450 genes was from the human promoter, except for CYP2C9, which was driven by the albumin promoter, and CYP1A1, CYP1A2, CAR and PXR which were driven off the corresponding murine promoters.

8HUM mice were further genetically altered by deleting *Rag2* using CRISPR/cas9-mediated gene editing in 8HUM zygotes (Taconic Biosciences GmbH, Germany). Breeding of mice from this process was carried out to re-generate 8HUM mice with a homozygous deletion of *Rag2*-8HUM\_ *Rag2*<sup>-/-</sup>-rendering the line immunodeficient for xenograft studies.

Animals were on a C57BL/NTac background and were bred, and experimental work carried out in the Medical School Resource Unit, University of Dundee. Mice were held at positive pressure in Techniplast Sealsave BlueLine micro-isolator cages, with Eco-Pure chip7D bedding (Datesand Group, UK) and *ad libitum* access to water and food-RM1 for maintenance, RM3 for breeding (Special Diet Services, UK). Temperature (20–24°C) and relative humidity (45–65%) were maintained in a 12-hour light-dark environment.

All animal work was approved by the Welfare and Ethical Treatment of Animals Committee, under Home Office Project (PAFCCC160) and personal licences (I94242D3D, IDFA32717, I372C0F97) under the Animals (Scientific Procedures) Act 1986, as amended by EU Directive 2010/63/EU.

Every effort was made to ameliorate animal suffering. Animals were inspected regularly by trained and experienced staff, with 24-hour access to veterinary advice, and consideration was given to socialisation by allowing time for settling into new (experimental) groups. In addition, environmental enrichment was routinely added to cages in the form of red plastic tunnels or nests, chew sticks and diet was supplemented by sunflower seeds.

On study completion, animals were sacrificed by exposure to a rising concentration of CO<sub>2</sub> and death confirmed by exsanguination, according to Schedule 1 of the Animals (Scientific Procedures) Act 1986.

### Experimental design

Adult female (>8 <22 weeks) mice were randomly allocated into control or experimental groups and allowed to adapt to their social setting for 7 d before study start. Cages were adjacent to each other on the same level of a ventilated rack, in the same room, for the study duration.

Neither animal staff nor experimenters were blinded to the identity of the mice or the experimental group in which they were placed, before, during or after the study.

Sample size: Although this work was considered preliminary in nature and the studies carried out as pilots, group sizes of  $n = 3-5$  were used, following consideration of power calculations using G\*Power,<sup>12</sup> with an effect size of 1.75 and power of 80%.

Data analysis: Dependencies of calculated tumour volumes versus time were analysed by non-linear regression using exponential growth and exponential decay functions (GraphPad Prism v6.05 software, Graphpad, US). Alternative, open source, software – R – can be found at <https://www.r-project.org>. Rate constants in both functions were constrained to positive values to maintain consistency with the function name. Values for plateau parameters in exponential decay function were set to zero.

## Protocol

A375 human melanoma cells (ATCC: CRL-1619; RRID:CVCL\_UD29) and 5555 murine melanoma cells<sup>13–15</sup> were grown as directed, with the latter subject to commercial murine pathogen testing (IDEXX Bioanalytics GmbH, Germany) and both to in-house mycoplasma testing (MycAlert Mycoplasma Detection kit, Lonza Rockland, USA) before use. Passage number was recorded for each study.

Cell lines were harvested on the morning of the study, kept on ice and transferred to the animal facility for use within 1 h. All animal work was carried out in the sterile environment of a Tecniplast CS5 Evo Changing station.

Mice were weighed, fur removed on one/both flanks by electric shaver and placed individually in a red plastic inhalation chamber connected to an anaesthetic machine (Vet-Tech Solutions, Congleton, UK), to which was connected an anaesthetic maintenance tube running into the changing station. General anaesthesia was induced using an isoflurane (Piramal Critical Care, UK)/oxygen mixture in a Series 3 vapouriser (O<sub>2</sub> flow rate 2l/min, isoflurane 3.5–4%) and maintained when the mouse was removed from the chamber by lying the animal on its front, snout placed just inside the end of the anaesthetic maintenance tube and the isoflurane/oxygen flow switched to the tube (O<sub>2</sub> flow rate 1.5l/min, isoflurane 1.5–2.5%). Prepared cells ( $3.5\text{--}5 \times 10^6$ , 100 µl in DMEM (ThermoFisher Scientific, UK) were taken up in a 1ml plastic syringe and injected subcutaneously (s.c.) to one or both flanks using a 25mm/23G needle [*Optional: cells can be re-suspended in ECM (Sigma), diluted 1:1 with DMEM*]. This procedure routinely took <3 min. Immediately after injection, the mouse was returned to its home cage, placed on its front and monitored during recovery, which routinely took <5 min. [*Optional: s.c. injection may be carried out immediately after removing mouse from the inhalation chamber, while still under general anaesthesia. However, particularly with immortalised human tumours, care must be taken to avoid self-injection; on safety grounds the maintenance anaesthesia route is strongly recommended.*]

In addition to routine welfare monitoring, mice were weighed and checked for tumour growth daily. Body weight was used in conjunction with a body scoring system.<sup>16</sup> Deviation from normal health, >10% body weight loss, or a body condition score of 2 or less was referred to the University Vet or Welfare Officer. If any animal appeared distressed, or a tumour ulcerated, the animal was removed from study and killed by a Schedule 1 method.

Once established, tumours were measured twice in two dimensions (maximum breadth and length) using digital calipers, by the same person to avoid interindividual variation. Treatment was also started at this point, mice receiving either vehicle or drug daily (p.o.).

Dabrafenib methanesulfonate (LC Laboratories, MA, USA) was prepared as a 6.3 mg/ml suspension in vehicle (0.5% (w/v) hydroxypropylmethylcellulose, 0.2% (v/v) Tween-80) after 10 min sonication in a water bath and administered daily (p.o.) at 5 ml/kg, and a dose of 31.5 mg/kg. This is equivalent to approximately 150 mg of dabrafenib base for a 70 kg human,<sup>17</sup> approximately half of the recommended daily dose (<https://dailymed.nlm.nih.gov/>).


Trametinib (LC Laboratories, MA, USA) was prepared as a 0.07048 mg/ml suspension in vehicle (0.5% (w/v) hydroxypropylmethylcellulose, 0.5% (v/v) Tween-20) and administered daily (p.o.) at 5 ml/kg, and a dose of 0.3524 mg/kg. This is equivalent to 2 mg of trametinib for a 70 kg human,<sup>17</sup> which is the recommended daily dose (<https://dailymed.nlm.nih.gov/>).

Tumour volume was estimated using the formula  $((\text{width} \times \text{width}) \times \text{length}) / 2$ .<sup>18</sup> Tumour length was also monitored, and mice in which tumour length reached 15mm (either individually or in total if tumours on both flanks) were sacrificed by a Schedule 1 method and blood, tissues and tumours harvested as appropriate for downstream analysis.

## Results

8HUM mice were used to determine syngeneic growth of the murine melanoma cell line, 5555, derived from a C57BL/6\_BRAF+LSL-BRAFV600E;Tyr::CreERT2+/*o* transgenic model<sup>13</sup> and reported by Hirata *et al.* as being sensitive to the selective BRAF inhibitor, and vemurafenib precursor, PLX4720<sup>19</sup> *in vitro*, but refractory to this drug *in vivo*.<sup>14</sup> More recently, the second-generation mutant BRAF inhibitor dabrafenib (in combination with the MEK inhibitor trametinib) has become standard of care in UK and Europe in the treatment of unresectable or metastatic BRAF<sup>V600</sup> mutant melanoma (<https://www.nice.org.uk/guidance/>).<sup>20</sup>


All data for this report are available online at.<sup>21,22</sup> As shown in **Figure 1**, 5555 cells were injected s.c. into one flank of adult female 8HUM mice, divided into two groups of five mice. After five days tumours had established in each animal and were measurable, at which point daily oral treatment with either vehicle or dabrafenib was started. While tumours in vehicle-treated mice continued to grow over the following two weeks, over the same period tumours in mice treated with dabrafenib became almost undetectable. These data demonstrate that C57BL/6-origin tumours can be grown in a




**Figure 1. Growth of a murine melanoma syngeneic graft in 8HUM mice and response to dabrafenib treatment.** Adult female 8HUM\_Rag2<sup>-/-</sup> mice (18–21 w, n = 5) were injected s.c. in one flank with  $3.5 \times 10^6$  5555 murine melanoma cells, in 100  $\mu$ l ECM diluted 1:1 with DMEM. Tumours were allowed to establish and on day five after implantation daily treatment was commenced with either vehicle (0.5% (w/v) hydroxypropylmethylcellulose, 0.2% (v/v) Tween 80; closed circles) or dabrafenib methanesulfonate (in vehicle, open circles) suspended at 6.3 mg/ml and administered at 5 ml/kg, such that dabrafenib dose administered was 31.5 mg/kg (arrow). Tumour measurements were taken three times weekly, then daily as required, and tumour volume calculated as detailed in Methods section. The study was terminated 15 days after implantation of cells. Data shown are mean tumour volume  $\pm$  SEM.

syngeneic manner, and that the BRAF<sup>V600</sup> mutant murine melanoma cell line is exquisitely sensitive to the BRAF inhibitor dabrafenib. We have also been able to reproduce the known induction of P450 CYP3A4 by dabrafenib in the humanized mice, further demonstrating the utility of the model in anticancer drug development (unpublished data).

By creating an immunodeficient variant of the 8HUM mouse line, where the *Rag2* locus is deleted, we extended work to xenografts with the BRAF mutant human melanoma cell line, A375. Figure 2 shows change in total mean tumour volume following s.c injection of A375 cells injected into both flanks of adult female 8HUM\_Rag2<sup>-/-</sup> mice. Daily treatment of these mice started 28 d after injection of cells, either with vehicle or dabrafenib (arrow); while the tumours in the former group continued to grow, tumours in the mice treated with the BRAF inhibitor shrank in size until by d35 (at which point



**Figure 2. Response of A375 human melanoma xenograft to dabrafenib treatment in 8HUM\_Rag2<sup>-/-</sup> mice.** Adult female 8HUM mice (11–19 w, n = 3) were injected s.c. in both flanks with  $4.4 \times 10^6$  A375 melanoma cells, in 100  $\mu$ l DMEM. Tumours were allowed to establish and on day 28 after implantation daily treatment was commenced with either vehicle (0.5% (w/v) hydroxypropylmethylcellulose, 0.2% (v/v) Tween-80; closed circles) or dabrafenib (in vehicle, open circles) suspended at 6.3 mg/ml and administered at 5 ml/kg, such that dabrafenib dose administered was 31.5 mg/kg (arrow). Tumour measurements were taken three times weekly, then daily as required, and total volume of tumours on both flanks was calculated as detailed in Methods section. The study was terminated on d 35 after implantation of cells, although one vehicle-treated animal had to be removed from the study on d 29 as its total tumour size approached the maximum permitted under legislation. Data shown are mean tumour volume  $\pm$  SEM.



**Figure 3. Response of A375 human melanoma xenograft to trametinib treatment in 8HUM\_Rag2<sup>-/-</sup> mice.** Adult female 8HUM mice (8–18w, n = 3 or 4) were injected s.c. in one flank with  $5 \times 10^6$  A375 melanoma cells, in 100  $\mu$ l DMEM. Tumours were allowed to establish and on day 22 after implantation daily treatment was commenced with either vehicle (0.5% (w/v) hydroxypropylmethylcellulose, 0.2% (v/v) Tween 80; closed circles) or trametinib (in vehicle, open circles) suspended at 0.07 mg/ml and administered at 5 ml/kg, such that trametinib dose administered was 0.35 mg/kg (arrow). Tumour measurements were taken three times weekly, then daily as required, and tumour volume calculated as detailed in Methods section. Vehicle-treated mice were sacrificed on d 30 after implantation of cells; trametinib treatment was discontinued (STOP) at that time for the drug-treated group to determine whether tumour re-growth would occur in the absence of drug. Data shown are mean tumour volume  $\pm$  SEM.

the vehicle-treated mice had to be sacrificed due to tumour size) there was a significant difference in the treatment effect between the two groups (Figure 2). The data from vehicle group follows the exponential growth dependency and does not fit with the exponential decay function. Conversely, the dabrafenib group data follows exponential decay dependency and does not fit the exponential growth function. These data clearly demonstrate not only that it is possible to grow a human melanoma cell line as a xenograft in this immunodeficient version of the 8HUM mouse model, but it is also possible to demonstrate sensitivity of A375 tumours to BRAF inhibitors.

Dabrafenib is used in a clinical setting in combination with the MEK inhibitor trametinib. We tested the ability of trametinib to stop tumour growth, using A375 cells injected s.c. in the flank of adult female 8HUM\_Rag2<sup>-/-</sup> mice (Figure 3). Daily treatment with vehicle or drug commenced on d 22 after cell injection (arrow), and in the following period tumours in mice treated with vehicle continued to grow until by d 30 they had reached the maximum size permitted. At this point (Figure 3, STOP) tumours in the 8HUM\_Rag2<sup>-/-</sup> mice had regressed to the point where they were essentially undetectable, and trametinib treatment was stopped. Interestingly, over the following 10 days, tumours began to regrow in the absence of treatment until they were again palpable and measurable, and continued to grow over the next week or so until the study was terminated on d 48 (Figure 3).

## Discussion and conclusions

In a previous publication<sup>6</sup> we have demonstrated the utility of the 8HUM model in better predicting human drug metabolism and disposition, and in the current report show how the 8HUM mouse and its immunodeficient variant 8HUM\_Rag2<sup>-/-</sup> are capable of hosting both syngeneic tumours and xenografts, respectively.

Although both rats and mice are used by industry in the drug development process, the utility of mice for growing xenografts, including patient-derived xenografts, and the development of ‘mouse clinical trials’,<sup>23</sup> along with the more advanced use of mice in genetically engineered models (such as 8HUM) means that increasingly mice are being considered more useful for drug development, especially in oncology.<sup>24</sup> While numbers of animals used in syngeneic or xenograft work in pre-clinical drug development are difficult to assess, the total will be significant given the number of drug candidates being tested across Pharma at any given time, and such growth of tumours *in vivo* is also carried out in other research areas, for example, toxicology. A PubMed search for papers published in 2019 found ~5,000 papers containing ‘xenograft’ in the title or abstract, illustrating the extent to which the 8HUM and 8HUM\_Rag2<sup>-/-</sup> models – modified as appropriate by gene editing to recapitulate disease models – may be able to address 3Rs issues by both **refinement**: generation of better, more human-relevant data, and **reduction** – use of fewer animals without loss of statistical power. Pre-clinical use of humanised models to prevent failure of a drug candidate during clinical testing because of species differences in drug disposition would undoubtedly save significant numbers of mice. They will also allow complex drug combinations to be tested and treatment regimens optimised in a manner which is not feasible by clinical trial and reduce the chances of drug-drug interactions.



The 8HUM has some limitations, and it should be noted that a minor complement of murine P450 enzymes remain, and that the Phase II enzymes are murine. These may potentially contribute to drug disposition, as may other pathways e.g., drug transporters. However, the advent of CRISPR/Cas9, as used here to delete the Rag2 locus in the 8HUM mouse, means that it should be relatively simple to additionally modify the 8HUM model to further enhance versatility.

### Author contributions

Conceptualization	Wolf, Henderson, Kapelyukh
Data Curation	McLaren, Henderson, Kapelyukh
Formal analysis	Kapelyukh, Henderson
Funding acquisition	Wolf, Henderson
Investigation	Kapelyukh, McLaren, Henderson
Methodology	Wolf, Kapelyukh, McLaren, Henderson
Project Administration	McLaren, Henderson
Resources	McLaren, Henderson
Supervision	Wolf, Henderson

### Data availability

#### Underlying data

Figshare: Underlying data for 'Improving the predictive power of xenograft and syngeneic anti-tumour studies using mice humanised for pathways of drug metabolism'. <https://doi.org/10.6084/m9.figshare.20060465.v1>.<sup>21</sup>

This project contains the following underlying data:

- Data file 1: FIG 1 BRI995 Weights&Tumours 280219.xlsx
- Data file 2: FIG 2 BRI1102 Weights&Tumour 010421.xlsx
- Data file 3: FIG 3 BRI1119 Weights&Tumour 210621.xlsx

#### Reporting guidelines

Figshare: ARRIVE checklist for 'Improving the predictive power of xenograft and syngeneic anti-tumour studies using mice humanised for pathways of drug metabolism'. <https://doi.org/10.6084/m9.figshare.20060465.v1>.<sup>22</sup>

Data are available under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/) (CC-BY 4.0)

### Acknowledgements

The staff of the Medical School Resource Unit at the University of Dundee are thanked for their assistance with animal work.

The mouse lines described in this manuscript were developed under a material transfer agreement between Taconic Biosciences and the University of Dundee.

Murine 5555 cells were a generous gift from Professor Richard Marais, Cancer Research UK Centre, University of Manchester, UK.

### References

1. Honek J: **Preclinical research in drug development**. *Medical Writing*. 2017; **26**: 5–8.
2. Dowden H, Munro J: **Trends in clinical success rates and therapeutic focus**. *Nat. Rev. Drug Discov.* 2019; **18**(7): 495–496. [PubMed Abstract](#) | [Publisher Full Text](#)
3. Harrison RK: **Phase II and phase III failures: 2013–2015**. *Nat. Rev. Drug Discov.* 2016; **15**(12): 817–818. [PubMed Abstract](#) | [Publisher Full Text](#)
4. Long JE, Jankovic M, Maddalo D: **Drug discovery oncology in a mouse: concepts, models and limitations**. *Future Sci. OA.* 2021; **7**(8): FSO737. [PubMed Abstract](#) | [Publisher Full Text](#)
5. Sun D, Gao W, Hu H, et al.: **Why 90% of clinical drug development fails and how to improve it?** *Acta Pharm. Sin. B.* 2022; **12**: 3049–3062. [PubMed Abstract](#) | [Publisher Full Text](#)

6. Henderson CJ, Kapelyukh Y, Scheer N, *et al.*: **An Extensively Humanized Mouse Model to Predict Pathways of Drug Disposition and Drug/Drug Interactions, and to Facilitate Design of Clinical Trials.** *Drug Metab. Dispos.* 2019; **47**(6): 601–615.  
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Duarte D, Vale N: **Evaluation of synergism in drug combinations and reference models for future orientations in oncology.** *Curr. Res. Pharmacol. Drug Discov.* 2022; **3**: 100110.  
[PubMed Abstract](#) | [Publisher Full Text](#)
8. Kersten K, de Visser KE, van Miltenburg MH, *et al.*: **Genetically engineered mouse models in oncology research and cancer medicine.** *EMBO Mol. Med.* 2017; **9**(2): 137–153.  
[PubMed Abstract](#) | [Publisher Full Text](#)
9. Byrne AT, Alferez DG, Amant F, *et al.*: **Interrogating open issues in cancer precision medicine with patient-derived xenografts.** *Nat. Rev. Cancer.* 2017; **17**(4): 254–268.  
[PubMed Abstract](#) | [Publisher Full Text](#)
10. Goto T: **Patient-Derived Tumor Xenograft Models: Toward the Establishment of Precision Cancer Medicine.** *J Pers Med.* 2020; **10**(3).  
[PubMed Abstract](#) | [Publisher Full Text](#)
11. Dudova Z, Conte N, Mason J, *et al.*: **The EurOPDX Data Portal: an open platform for patient-derived cancer xenograft data sharing and visualization.** *BMC Genomics.* 2022; **23**(1): 156.  
[PubMed Abstract](#) | [Publisher Full Text](#)
12. Faul F, Erdfelder E, Buchner A, *et al.*: **Statistical power analyses using G\*Power 3.1: tests for correlation and regression analyses.** *Behav. Res. Methods.* 2009; **41**(4): 1149–1160.  
[PubMed Abstract](#) | [Publisher Full Text](#)
13. Dhomen N, Reis-Filho JS, da Rocha DS, *et al.*: **Oncogenic Braf induces melanocyte senescence and melanoma in mice.** *Cancer Cell.* 2009; **15**(4): 294–303.  
[PubMed Abstract](#) | [Publisher Full Text](#)
14. Hirata E, Girotti MR, Viros A, *et al.*: **Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin beta1/FAK signaling.** *Cancer Cell.* 2015; **27**(4): 574–588.  
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Roulstone V, Pedersen M, Kyula J, *et al.*: **BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress.** *Mol. Ther.* 2015; **23**(5): 931–942.  
[Publisher Full Text](#)
16. Ullman-Cullere MH, Foltz CJ: **Body condition scoring: a rapid and accurate method for assessing health status in mice.** *Lab. Anim. Sci.* 1999; **49**(3): 319–323.  
[PubMed Abstract](#)
17. Reagan-Shaw S, Nihal M, Ahmad N: **Dose translation from animal to human studies revisited.** *FASEB J.* 2008; **22**(3): 659–661.  
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Faustino-Rocha A, Oliveira PA, Pinho-Oliveira J, *et al.*: **Estimation of rat mammary tumor volume using caliper and ultrasonography measurements.** *Lab Anim (NY).* 2013; **42**(6): 217–224.  
[PubMed Abstract](#) | [Publisher Full Text](#)
19. Tsai J, Lee JT, Wang W, *et al.*: **Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.** *Proc. Natl. Acad. Sci. U. S. A.* 2008; **105**(8): 3041–3046.  
[PubMed Abstract](#) | [Publisher Full Text](#)
20. Long GV, Stroyakovskiy D, Gogas H, *et al.*: **Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.** *Lancet.* 2015; **386**(9992): 444–451.  
[PubMed Abstract](#) | [Publisher Full Text](#)
21. Henderson C, Wolf CR, Kapelyukh Y, *et al.*: **FIGS 1-3 NC3Rs F1000 submission 122987.xlsx.** [figshare.](#) [Dataset]. 2022.  
[Publisher Full Text](#)
22. Henderson C, Wolf CR, Kapelyukh Y, McLaren A, *et al.*: **ARRIVE Checklist - Full.pdf.** [figshare.](#) [Dataset]. 2022.  
[Publisher Full Text](#)
23. Guo S, Jiang X, Mao B, *et al.*: **The design, analysis and application of mouse clinical trials in oncology drug development.** *BMC Cancer.* 2019; **19**(1): 718–731.  
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Long JE, Jankovic M, Maddalo D: **Drug discovery oncology in a mouse: concepts, models and limitations.** *Future Sci. OA.* 2021; **7**(8): FS0737.  
[PubMed Abstract](#) | [Publisher Full Text](#)

# Open Peer Review

Current Peer Review Status:  

---

## Version 2

Reviewer Report 11 April 2023

<https://doi.org/10.5256/f1000research.145248.r167839>

© 2023 Goldring C. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



### Chris Goldring

MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK

I would consider that the authors responses are satisfactory, and would be satisfied that this work is now acceptable for indexing.

**Competing Interests:** No competing interests were disclosed.

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

Reviewer Report 29 March 2023

<https://doi.org/10.5256/f1000research.145248.r167840>

© 2023 Prough R. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



### Russ Prough

Hepatobiology&Toxicology Program, University of Louisville, Louisville, KY, USA

The Authors have revised the areas of my concern and I find it acceptable for indexing.

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** drug metabolism, CYPs

**I confirm that I have read this submission and believe that I have an appropriate level of**

expertise to confirm that it is of an acceptable scientific standard.

---

**Version 1**

Reviewer Report 13 February 2023

<https://doi.org/10.5256/f1000research.135046.r160109>

© 2023 Goldring C. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Chris Goldring**

<sup>1</sup> MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK

<sup>2</sup> MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK

This is an important preliminary report that will be of value to the academic and pharmaceutical drug development scientists.

Some specific points:

Methodologically, this looks to be a preliminary but robust report. The lack of characterisation of the tumours post-mortem is an issue that the authors could address using conventional histological characterisation. This is not a request that should not significantly impede time to publication, but would add more depth to the findings.

In the abstract –“The poor predictive power of animal models in pre-clinical studies is predominantly due to lack of efficacy or safety reasons, which in turn can be attributed mainly to the significant species differences in drug metabolism between humans and animals.” This is largely correct for older traditional investigative compounds, however as drug development pipelines have evolved, especially with the advent of more large molecule development, the issue of target-drug conservation of pharmacodynamic effect becomes very relevant. The authors should make some account of this (given that the two agents looked at in this report are conventional small molecule inhibitors).

Pharma largely uses rat models, for various reasons. The authors should note this in the context of their own mouse model.

**Is the work clearly and accurately presented and does it cite the current literature?**

Yes

**Is the study design appropriate and is the work technically sound?**

Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**

Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**

Yes

**Are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions drawn adequately supported by the results?**

Partly

**Competing Interests:** No competing interests were disclosed.

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.**

Author Response 06 Mar 2023

**Colin Henderson**

*Point 1: Pathological characterisation*

It should be noted that the xenografts used in this study were derived from a human cell line and not from a solid tumour. In addition, tumour samples are not available for the drug treated groups because of the effectiveness of the treatments used. On this basis we feel adding histopathological data would add little to the main conclusions of the study.

*Point 2: Species differences in drug metabolism remain a significant impediment in drug development*

In the light of the Reviewer's comment, we have changed the sentence to read "Species differences in drug metabolism can be a major impediment to drug discovery programmes, for example in the demonstration of drug efficacy as a consequence of high rates of metabolism in rodents. Furthermore, the spectrum of metabolites produced, which can be pharmacologically active, is often significantly different between humans and rodents. These factors can confound the extrapolation of animal data to man particularly when drug combination therapies are being tested".

*Point 3:*

The Reviewer is correct to point out that both rats and mice are used by industry in the drug development process. However, the utility of mice for growing xenografts, including patient-derived xenografts, and the development of 'mouse clinical trials', along with the more advanced use of mice in genetically engineered models (such as 8HUM) means that increasingly mice are being considered more useful for drug development, especially in oncology. A sentence to this effect has been placed in the Discussion, and additional references added.

**Competing Interests:** None.

Reviewer Report 19 January 2023

<https://doi.org/10.5256/f1000research.135046.r159796>

© 2023 Prough R. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Russ Prough**

<sup>1</sup> Hepatobiology&Toxicology Program, University of Louisville, Louisville, KY, USA

<sup>2</sup> Hepatobiology&Toxicology Program, University of Louisville, Louisville, KY, USA

The manuscript in general is clearly written and leads the reader through the results. The statistical details providing valid conclusions is well documented. The Authors have developed a unique murine model to provided data on human metabolism. Past reports document the utility of model as being useful to document. A couple specific questions arise:

1. If the authors had used the original mouse line (with the Rag2 gene present), would the results have been the same or less sensitive to the anti-cancer drugs?
2. If that data exists, has it been published? If not would inclusion of such data strengthen the current manuscript. This would document the importance of the Rag2 KO.
3. Some anti-cancer drugs induced their own metabolism. Has this been studied for Dabrafenib or Tremetinib?

**Is the work clearly and accurately presented and does it cite the current literature?**

Yes

**Is the study design appropriate and is the work technically sound?**

Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**

Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**

Yes

**Are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions drawn adequately supported by the results?**

Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** drug metabolism, CYPs

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.**

Author Response 06 Mar 2023

**Colin Henderson**

*Point 1: If the authors had used the original mouse line (with the Rag2 gene present), would the results have been the same or less sensitive to the anti-cancer drugs?*

The human cell line (A375) would not have grown in an immunocompetent 8HUM line.

*Point 2: If that data exists, has it been published? If not would inclusion of such data strengthen the current manuscript. This would document the importance of the Rag2 KO.*

Data does not exist for the reason outlined above.

*Point 3: Some anti-cancer drugs induced their own metabolism. Has this been studied for Dabrafenib or Trametinib?*

Dabrafenib is principally metabolised by CYP2C8 and CYP3A4, and in common with many drugs, can induce its own metabolism (see - Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib, (2019) Puszkiel, A. et al., PMID: 30094711). With regard to Trametinib, the position is less clear. We have also been able to reproduce the known induction of P450 CYP3A4 by dabrafenib in the humanized mice, further demonstrating the utility of the model in anticancer drug development (unpublished data), and a sentence to this effect has been added to the text of the Results section.

**Competing Interests:** None.

---

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact [research@f1000.com](mailto:research@f1000.com)

**F1000Research**